The clinical effect of Silodosin for lower urinary tract symptoms after permanent prostate brachytherapy

The clinical effect of Silodosin for lower urinary tract symptoms after permanent prostate brachytherapy - The effect of Silodosin for LUTS after permanent prostate brachytherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004146

Enrollment

Registered

2010-10-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Silodocin 8mg/day Silodocin 4mg/day

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Pathologically proven prostate cancer. Patient who underwent prostate brachytherapy or prostate brachyterapy in combination with external beam radiation therapy. Written informed consent can be obtained.

Exclusion criteria

Exclusion criteria: Patient with allergy against Silodocin. Patient with neurogenic bladder, bladder neck constructure, urethral stenosis, vesical stone, or large bladder diverticulum. Patient with active urinary tract infection. Patient with severe renal dysfunction. Patient with severe liver disease. Patient who is considered to be inapropriate for this study by physisian.

Design outcomes

Primary

Measure	Time frame
IPSS score, QOL score, OABSS score, IIEF-5 score, SF-8 score, EPIC score, Uroflowmetry Qmax	—

Secondary

Measure	Time frame
safety	—

Countries

Japan

Contacts

Public ContactMototsugu Muramaki

Kobe University Graduate School of Medicine Division of Urology

muramaki@med.kobe-u.ac.jp078-382-6155

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026